Sangamo exits ST-920 gene therapy assets in Chapter 11 sale to PTC for USD 111 million
Bitget2026/09/21 20:01- Sangamo Therapeutics completed the sale of ST-920 Fabry gene-therapy assets to PTC Therapeutics on Sept. 17, 2026.
- Consideration totaled USD 111 million in cash at closing.
- Deal includes up to USD 100 million of milestone-based contingent payments.
- PTC also assumed certain specified liabilities tied to the transferred assets.
- Common stock remains suspended from Nasdaq trading, now quoted on OTCID Basic Market under symbol SGMOQ.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ekopak Expands Wastewater Treatment Plant at Mark Anthony Brewing
Vodafone (VOD.US) Swings to Loss in First Half, German Operations Major Drag
Vodafone (VOD.US) released its financial results for the first half of fiscal year 2027.
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
AI Cloud Sector Faces a Key Moment: CoreWeave (CRWV.US) Set to Announce Earnings, Wells Fargo Remains Bullish
CoreWeave (CRWV.US) will release its third-quarter financial report after the U.S. stock market closes on Tuesday. This is seen as a key test for the strength of the new AI cloud sector.
Crypto prices
More
